<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Dalsgaard | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/beechbronze01/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/beechbronze01/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Dalsgaard.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">5bde2630f2997529919d044d4a9b1ae9</guid>
				<title>Dalsgaard posted an update: Special emphasis will be given on how RGD-binding integrins [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41327/</link>
				<pubDate>Sat, 08 Feb 2025 08:06:29 -0800</pubDate>

									<content:encoded><![CDATA[<p>Special emphasis will be given on how RGD-binding integrins can modulate the intricate molecular pathways and regulate the underlying pathological mechanisms. For instance, the interplay between integrins and key molecular players such as growth factors, cytokines and enzymes will be summarized. In addition, recent clinical advances linked to&hellip;<span class="activity-read-more" id="activity-read-more-41327"><a href="http://www.nationalboardinstitute.com/activity/p/41327/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f534e917c814db7fbcc27d4abfb45ad6</guid>
				<title>Dalsgaard posted an update: 39, 95% CI 1.53-12.67) and medical comorbidity (OR=1.69, 95% [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38738/</link>
				<pubDate>Wed, 05 Feb 2025 08:07:32 -0800</pubDate>

									<content:encoded><![CDATA[<p>39, 95% CI 1.53-12.67) and medical comorbidity (OR=1.69, 95% CI 1.00-2.86).</p>
<p> The depression risk is associated with a history of depressive disorder and medical comorbidity in patients with AS and COPD. Medical history is the leading risk factor for depression during confinement. <a href="https://www.selleckchem.com/products/gw9662.html" rel="nofollow ugc">selleck</a> It is recommended to carry out studies with many&hellip;<span class="activity-read-more" id="activity-read-more-38738"><a href="http://www.nationalboardinstitute.com/activity/p/38738/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f86dde44c662339ab7abc4bd1a6a82b9</guid>
				<title>Dalsgaard posted an update: DT56a is a possible alternative for the treatment of acute [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36069/</link>
				<pubDate>Sun, 02 Feb 2025 08:05:11 -0800</pubDate>

									<content:encoded><![CDATA[<p>DT56a is a possible alternative for the treatment of acute climacteric syndrome. In the Central European population, the efficacy of a daily dose of 644 mg corresponds with the effects observed in the Mediterranean population (Tab. 2, Fig. 3, Ref. 21). Text in PDF <a href="http://www.elis.skKEY" rel="nofollow ugc">http://www.elis.skKEY</a> WORDS DT56a, climacteric syndrome, menopause, non-hormonal&hellip;<span class="activity-read-more" id="activity-read-more-36069"><a href="http://www.nationalboardinstitute.com/activity/p/36069/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7a04fadef9214e94d79c9a9236ec5e75</guid>
				<title>Dalsgaard became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/31041/</link>
				<pubDate>Tue, 28 Jan 2025 16:05:59 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>